Company Description
Pluri Inc., a biotechnology company, engages in the research, development, and manufacture of cell-based products, cell therapeutics, and cell-based technologies for various industries.
It develops placenta-based cell therapy product candidates for the treatment of inflammatory, muscle injuries, and hematologic conditions; and a novel immunotherapy platform.
The company’s product candidates include PLX-PAD, that is composed of maternal mesenchymal stromal cells originating from the placenta for the treatment of various indications, such as acute muscle injuries following hip fracture, acute respiratory distress syndrome due to COVID-19, peripheral artery disease, intermittent claudication, and critical limb ischemia; PLX-R18, is composed of fetal MSC like cells originating from the placenta for the treatment of hematopoietic complications of the H-ARS, and phase I trial to treat hematopoietic cell transplantation; and allogeneic MAIT cell therapy platform.
It also offers cell manufacturing services; cell-based coffee; and develops and commercializes cultivated meat products.
The company operates in the field of regenerative medicine, food-tech, CDMO, and agtech. It has collaboration agreement with Bar-Ilan University to advance cancer immunotherapy for solid tumors.
The company was formerly known as Pluristem Therapeutics Inc. and changed its name to Pluri Inc. in July 2022.
Pluri Inc. was incorporated in 2001 and is based in Haifa, Israel.
| Country | Israel |
| Founded | 2001 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 118 |
| CEO | Yaacov Yanay |
Contact Details
Address: Building No. 5, MATAM Advanced Technology Park Haifa, 3508409 Israel | |
| Phone | 972 74 710 8600 |
| Website | pluri-biotech.com |
Stock Details
| Ticker Symbol | PLUR |
| Exchange | NASDAQ |
| Fiscal Year | July - June |
| Reporting Currency | USD |
| CIK Code | 0001158780 |
| CUSIP Number | 72942G104 |
| ISIN Number | US72942G1040 |
| Employer ID | 98-0351734 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Yaacov Yanay | President, Chief Executive Officer and Director |
| Liat Zalts | Chief Financial Officer and Treasurer |
| Lior Raviv | Chief Technology Officer |
| Dr. Arthur Machlenkin Ph.D. | Chief Scientific Officer |
| Efrat Livne-Hadass | Chief Wellbeing Officer |
| Orly Amiran | Chief Quality Officer |
| Efrat Kaduri | Chief Business Development Officer of Pharma |
| Nimrod Bar Zvi | Chief Commercial Officer |
| John Dvor | Executive Vice President North America |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Nov 12, 2024 | 10-Q | Quarterly Report |
| Oct 1, 2024 | 8-K | Current Report |
| Sep 18, 2024 | 10-K | Annual Report |
| Jul 23, 2024 | 8-K | Current Report |
| Jul 8, 2024 | 8-K | Current Report |
| Jul 2, 2024 | 8-K | Current Report |
| Jun 26, 2024 | 8-K | Current Report |
| Jun 18, 2024 | 8-K | Current Report |
| May 31, 2024 | 8-K | Current Report |
| May 9, 2024 | S-8 | Securities to be offered to employees in employee benefit plans |